Picornaviruses are the most commonly encountered infectious agents in mankind. They typically cause mild infections of the gastrointestinal or respiratory tract, but sometimes also invade the central nervous system. There, they can cause severe diseases with long-term sequelae and even be lethal. The most famous picornavirus is polio that was a huge burden for mankind for a long time. A successful vaccination campaign brought polio close to eradication, but neurological diseases caused by other picornaviruses have been increasingly reported since the late 1990s. In this review we focus on enterovirus 71, coxsackievirus A16, enterovirus 68 and human parechovirus 3 that have recently drawn attention because of their links to severe neurological diseases. We discuss the clinical relevance of these viruses, the primary role of humoral immunity to control them and summarize current knowledge on neutralization of such viruses by antibodies.
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INTRODUCTION 33
Picornaviridae is one of the largest viral families. According to the International 34 Committee on Taxonomy of Viruses (ICTV) it contains 31 genera that together 35 enclose 54 viral species (Adams et al., 2015) . They infect diverse hosts, from lower 36 vertebrates to mammals. The genera Kobuvirus, Salivirus, Cosavirus, Cardiovirus, 37 Hepatovirus, Parechovirus, and Enterovirus infect humans ( Fig. 1) (Tapparel et al., 38 2013) . 39
Hepatovirus A, Parechovirus A and multiple enterovirus genera can cause 40 symptomatic infections in humans. They typically result in mild disease of 41 gastrointestinal or respiratory tract, but sometimes are associated with severe 42 conditions. For instance, coxsackievirus B (CVB) type 3 has an established role in 43 viral myocarditis (Fairweather et al., 2012) , and CVB4 is well-documented as a viral 44 trigger of type 1 diabetes onset (Yeung et al., 2011) . 45
Several human picornaviruses can target the central nervous system (CNS) 46 and cause severe neurological diseases. The most well known of them is polio (PV). It 47 caused outbreaks of flaccid paralytic disease in children and was a health care burden 48 for a long time, until development of vaccines and a worldwide vaccination campaign 49 brought it close to eradication (Morales et al., 2016) . However, other neurotropic 50 picornaviruses still have potential to cause outbreaks of neurological diseases, such as 51 severe and life-threatening meningoencephalitis, encephalitis or acute flaccid 52 paralysis (AFP). A recent metagenomic study identified members of Cosavirus, 53
Cardiovirus, Kobuvirus, Enterovirus and Parechovirus genera in clinical samples 54 from AFP children (Victoria et al., 2009 ). This study corroborated epidemiological 55 and experimental work that has already established firm connections between 56 PV and also from EV71 patient material (Chen et al., 2007; Daley et al., 2005; Ren & 82 Racaniello, 1992; Wong et al., 2008) . 83
The second mechanism proposes that during viremia viruses cross the blood-84 brain barrier (BBB) and infect neural cells. Indeed, high levels of viremia and 85 inflammation can decrease tight junction protein expression, disrupt BBB integrity 86 and facilitate viral invasion (Fig. 2 (c) ) (Chai et al., 2014; Daniels et al., 2014) . 87
Although the inflammation-induced BBB breakdown has not been directly shown for 88 picornaviruses, their prolonged viremia correlates with severe CNS infections and 89 supports this possibility (Cheng et al., 2014) . Picornaviruses can also cross the BBB 90 in an active manner: PV can move through the BBB at a rate comparable to a BBB-91 crossing antibody ( Fig. 2 (d) ) (Yang et al., 1997) . Such trafficking happens 92 independently of the PvR and appears to rely on transferrin receptor 1 (Mizutani et 93 al., 2016) . 94
The third mechanism of neurotropism involves migration of infected cells, 95 such as dendritic cells, monocytes, macrophages, T-and B-cells and nestin + myeloid 96 cells to the CNS, and is called a "Trojan horse" invasion ( Fig. 2 (e) ) (Tabor-Godwin 97 et al., 2010; Vuorinen et al., 1996; Wahid et al., 2005) . 98
Neurotropic picornaviruses often target different regions of the CNS, and 99 hence vary in their clinical manifestations. Infection of meningeal cells or cells of the 100 ventricular lining results in aseptic meningitis-a non-bacterial inflammation of 101 tissues lining the brain (Irani, 2008) . Infection of neurons with subsequent 102 inflammation of brain parenchyma results in encephalitis that can have long-term 103 sequelae or be fatal (Verboon-Maciolek et al., 2008) . Inflammation of the spinal cord 104 grey matter results in myelitis and can lead to limb paralysis (Irani, 2008) . All these 105 conditions can be caused by different picornaviruses and their incidences are highest 106 in children (Nicolosi et al., 1986) . 107
NEUROTROPIC PICORNAVIRUSES IN FOCUS 108
Confirmed neurotropic picornaviruses are members of Enterovirus and Parechovirus 109 genera. The genus Enterovirus includes many recognized pathogens, such as PV, 110 CVA, coxsackieviruses B (CVB), rhinoviruses and EV, whereas genus Parechovirus 111
is smaller and includes one human pathogenic species-Parechovirus A. The 112 infections are common, and in the US alone over 10 million symptomatic EV cases 113 are reported annually (Strikas et al., 1986) . Human EV and HPeV can be responsible 114 for about 80% of aseptic meningitis cases (Esposito et al., 2014) and 11% of reported 115 encephalitis cases (Koskiniemi et al., 2001) . Several types of EV can trigger myelitis 116 with limb paralysis (Kincaid & Lipton, 2006) . 117
Not all serotypes of EV and HPeV cause CNS diseases. Enteroviruses 118 associated with CNS infections include PV types 1, 2 and 3, echovirus types 9, 11, 30 119 and 33, CVA type 16, CVB types 3 and 5 (Mistchenko et al., 2006) , EV types 68 120 (Messacar et al., 2015) and 71 (McMinn et al., 2001) . Parechovirus CNS infections 121 are almost exclusively caused by HPeV3 (Piralla et al., 2014) . In this review we will 122 discuss EV71, CVA16, EV68 and HPeV3 that have gained attention due to their 123 recent emergence and connection with CNS infections. 124 125 Enterovirus 71 and Coxsackievirus A16 126 EV71 was initially discovered as a CNS-targeting picornavirus: the first isolates came 127 from two children with neurological symptoms in 1969 in California (Schmidt et al., 128 1974) . In 1973 it was identified as an etiological agent for hand-foot-and-mouth 129 disease (HFMD), a childhood exanthema characterized by rashes on the palms and 130 soles, oral ulcers and brief febrile illness, but cases of aseptic meningitis were also 131 observed (Hagiwara et al., 1978) . In the middle of 1970s it caused a few small 132 outbreaks of aseptic meningitis in the USA, Europe and Australia (Alexander et al., 133 1994; Blomberg et al., 1974; Ishimaru et al., 1980; Kennett et al., 1974) and two 134 rather large outbreaks of polio-like disease in Bulgaria and Hungary that affected 135 predominantly infants with up to 21% of paralytic manifestations of which over a 136 quarter were lethal Nagy et al., 1982; Shindarov et al., 137 1979) . 138 EV71 became a major health care threat in the late 1990s after a series of large 139 outbreaks across the Asia-Pacific region. Most of the affected individuals were 140 children; they often developed HFMD or herpangina, but upper respiratory tract 141 infections (URTI) and non-specific rashes were occasionally observed. A fraction of 142 EV71 infections had neurological and systemic manifestations, but, unlike earlier 143 outbreaks when aseptic meningitis was the most frequent neurological manifestation, 144 more recent outbreaks were characterized with the increased incidence of much more 145 severe brainstem encephalitis and high mortality rate (Chan et al., 2000; Huang et al., 146 1999) . The first and largest outbreak in this series occurred in 1998 in Taiwan. 147
Sentinel physicians reported almost 130,000 cases of HFMD, and over 400 cases of 148 severe neurological involvement with almost 20% mortality rate (Ho et al., 1999b) 149 and in total that outbreak affected about 1.5 million people (Solomon et al., 2010) . In 150 1999 an outbreak in Western Australia resulted in 6000 cases of HFMD and 29 cases 151 of CNS disease, at least nine of which were severe and four developed long-term 152 neurological sequelae (McMinn et al., 2001) . EV71 outbreaks, most of which had 153 lethal cases, continued in Korea, Singapore, Japan, Malaysia, Vietnam and Thailand 154 (Solomon et al., 2010) . In 2008 there was a large EV71 outbreak in China with almost 155 half a million reported HFMD cases and 122 fatal cases (Yang et al., 2009) . The virus 156 kept on circulating in China and contributed to HFMD cases with CNS complications 157 and fatalities at least until 2014 (Liu et al., 2015a) . By then, over 7.5 million cases of 158 HFMD were reported in China alone, of which over 80,000 had neurological 159 involvement and Chinese government declared the development of measures to 160 control EV71 spread as a national priority (Liu et al., 2015b) . 161
Enterovirus 71 infections have been lately detected in Europe, including 162
Denmark, France, Spain and the Netherlands, and although the incidence of EV71 163 infections there is low, occasional lethal cases have already been reported (Cabrerizo 164 et al., 2014; Fischer et al., 2014; van der Sanden et al., 2011; Schuffenecker et al., 165 2011) . Interestingly, German researchers have recently described a case of pediatric 166 encephalitis caused by a novel EV71 genotype that likely arose from a recombination 167 event (Karrasch et al., 2016) . Although no epidemic activity of EV71 has so far been 168 reported in Europe, the European Centre for Disease Prevention and Control (ECDC) 169 risk assessment reported increased detections of EV71 in the first half of 2016 as 170 compared to previous years, necessitating preparedness to control EV71 spread in 171
Europe (ECDC, 2016) . 172
Importantly, EV71 often alternates or co-circulates with other Enterovirus A 173 genotypes, mostly with CVA16, another recognized HFMD agent. Coxsackievirus 174 A16 also predominantly infects children but, unlike EV71, typically causes milder 175 symptoms and has much lower morbidity and mortality rate. In a comparative study 176 of 177 EV71 and 64 CVA16 patients in Taiwan, only 6.3% of CVA16 infections 177 developed aseptic meningitis, whereas 32% of EV71 cases resulted in aseptic 178 meningitis, encephalitis, polio-like syndrome, encephalomyelitis and fatal pulmonary 179 edema of which 7.9% were lethal . However, occasional severe 180 and fatal CVA16 cases have been reported in USA (Wright et al., 1963) , Taiwan 181 (Wang et al., 2004) , France (Legay et al., 2007) , Japan (Goto et al., 2009) , and China 182 (Chen et al., 2015) . 183
The outbreaks of CVA16 were documented in Canada (1957) (Robinson et al., 184 1958) , Australia (1991) (Ferson & Bell, 1991) , England and Wales (1994) (Bendig & 185 Fleming, 1996) and India (2009) (Kar et al., 2013) and were linked to HFMD. It co-186 circulated with EV71 in 1998 during the unprecedented HFMD epidemic in Taiwan 187 (Ho et al., 1999a) and continued circulating in Taiwan becoming dominant in years 188
2002 and 2003 (Chang, 2008) . The co-circulation of CVA16 and EV71 was 189 documented during HFMD outbreaks in Vietnam in 2005 (Tu et al., 2007) and in 190 China in 2008 onwards (Liu, 2014) . In Singapore CVA16 was the major cause of 191 HFMD epidemics in years 2002, 2005 and 2007, whereas in 2006 it was EV71 (Ang 192 et al., 2009). 193 Co-circulation of EV71 and CVA16 allows viral co-infections (He et al., 2013) 194 and recombination, which happened during the HFMD outbreak in China (Zhang et 195 al., 2010a) . Recombination between EV71 and CVA16 and accumulation of point genetically it is an enterovirus, EV68 shares properties of both entero-and 203 rhinoviruses and in most cases causes respiratory infections (Oberste et al., 2004) . It 204 hospitalizations and one death (Khan, 2015) . In 2016 EV68 was detected in patients 230 with neurological manifestations in the Netherlands, France, UK, Italy, Portugal and 231
Germany (ECDC, 2016) . 232
Intriguingly, the 2014 EV68 outbreak in North America overlapped with an 233 outbreak of a polio-like disease with the brain stem and the spinal cord grey matter 234 lesions and AFP. Infection with EV68 was confirmed in 5 out of 11 (45%) of the 235 American AFP patients (Messacar et al., 2015) . Furthermore, EV68 has been also 236 detected in four cases of AFP in Canada, two in Norway and one in France (Khan, 237 2015; Lang et al., 2014; Pfeiffer et al., 2015) . A recent retrospective study identified 238 EV68 in respiratory secretions from 12 of 25 (48%) patients with sporadic paralysis, 239 strengthening the EV68 link to CNS disease (Greninger et al., 2015) . Interestingly, all 240 the EV68 strains identified in association with paralytic disease formed a distinct 241 genetic cluster suggesting ongoing emergence and adaptation of this virus (Du et al., 242 2015) . Direct linkage of EV68 to neurological disease has been complicated by 243 difficulties to detect EV68 or its RNA in patients' CSF and so far only two studies 244 succeeded to detect EV68 in patients' CSF (Khetsuriani et al., 2006; Kreuter et al., 245 2011 ). However, we should note that other neurological picornaviruses-PV and 246 EV71-are also rarely recovered from the CSF, and therefore neurological 247 involvement of EV68 cannot be ruled out on the basis of negative CSF samples. 248
The incidence of EV68 has clearly increased over the last decade. Although 249 this observation could be related to significant improvements in the detection 250 techniques, the accumulating clinical data suggests that EV68 should be considered 251 an emerging pathogen. The concerns raised by respiratory EV68 infections and 252 especially by their possible link to AFP necessitate careful surveillance of the virus 253 spread, detailed studies of its pathogenesis and evolution and development of 254 preventative and/or treatment options. 255 256
Human parechovirus 3 257
Human parechovirus 3 belongs to species A within genus Parechovirus and is 258 the second most common human parechovirus (Wolthers et al., 2008) . HPeV3 was 259 isolated in 1999 from an infant with severe CNS disease (Ito et al., 2004) , and since 260 then it has been recognized as the most or second most prevalent virus causing CNS 261 infections in infants under 3 months old (Harvala et al., 2009 (Harvala et al., , 2011 Piralla et al., 262 2014; van der Sanden et al., 2008) . Outbreaks of HPeV3 usually occur in summer-263 autumn seasons and have a distinct biennial pattern (Harvala et al., 2011; Wolthers et 264 al., 2008) . They have been documented in Europe (Benschop et al., 2006) , North 265
America (Boivin et al., 2005) , Asia (Yamamoto et al., 2009) , and Australia 266 (Cumming et al., 2015) and are regularly associated with a variety of clinical 267 presentations, from mild gastrointestinal or respiratory illness to life-threatening 268 conditions in neonates (Esposito et al., 2014; Harvala et al., 2011; Tapia et al., 2008) . 269
It can cause systemic infections with possible neurological involvement in infants that 270 are collectively described as "sepsis-like illnesses" (Benschop et al., 2006; 271 Selvarangan et al., 2011; Wolthers et al., 2008) . Such illnesses typically present with 272 fever, seizures, irritability, respiratory and gastrointestinal problems and occasional 273 rash being indistinguishable from severe EV infections (Shoji et al., 2013; Verboon-274 Maciolek et al., 2008) . The fraction of symptomatic HPeV3-infected infants that 275 develop sepsis-like illness can exceed 80%; most of such patients require 276
hospitalization and up to one third of them are admitted to the ICU (Schuffenecker et 277 al., 2012; Selvarangan et al., 2011; Shoji et al., 2013) . The CNS symptoms of 278
HPeV3 infection can include meningitis, meningoencephalitis, encephalitis or 279 cerebral hemorrhage with occasional white matter alterations 280 Kurz et al., 2015) . Whereas HPeV3 meningitis typically has good prognosis, 281 meningoencephalitis entailing white matter alterations may have long-term sequelae 282 such as cerebral palsy, learning disabilities, epilepsy or visual impairment (Verboon-283 Maciolek et al., 2008) . In addition, HPeV3 is occasionally associated with 284 hemophagocytic lymphohistiocytosis (Aviner et al., 2014) and sudden death 285 syndrome in infants (Schuffenecker et al., 2012) . Furthermore, in Japan it was linked 286 to myositis in children and epidemic myalgia in adults (Mizuta et al., 2013; 287 Yamamoto et al., 2015) . Fatal cases of HPeV3 infections are known: they resulted 288 from encephalitis in the absence of an immune response and sometimes also involved 289 white matter necrosis van Zwol et al., 2009) . 290
Overall, HPeV3 represents a significant threat to neonatal health care. The 291 incidence of HPeV3 infections and number of CNS disease cases increases (Harvala 292 et al., 2011) with no treatment options available necessitating search for antivirals and 293 understanding of HPeV neutralization by antibodies (Wildenbeest et al., 2010) . 294
295

NEUTRALIZING ANTIBODIES IN PICORNAVIRUS INFECTIONS 296
Like with other viruses, the severity and outcome of picornavirus infections depends 297 both on the viral and host factors. Host immune status is a key regulator of infection, 298 and failure to mount an appropriate response inevitably leads to severe disease. The 299 viral infection is detected by the specific pattern recognition receptors of the innate 300 immunity that establish a complex signalling network, triggering the expression of 301 antiviral genes in infected cells and the activation of specific adaptive responses 302 (Dotzauer & Kraemer, 2012) . The adaptive responses rely on the specific populations 303
of T-cells and antibody-producing B-cells. Although both innate and cellular adaptive 304 immunity are essential, a large body of evidence indicates that efficient production of 305 specific antibodies by the B-cells is primary for the control of picornaviral infections. 306
Picornaviruses typically infect children, likely due to their naive immune 307 system. Severe picornavirus infections in healthy adults are uncommon. However, 308 immunocompromised adults, in particular those with impaired B-cell responses, are 309 susceptible to prolonged and/or severe picornavirus infections. For example, patients 310 with X-linked agammaglobulinemina (XLA) have markedly reduced levels of B-cells 311 and serum antibodies and are susceptible to enterovirus infections (Halliday et al., 312 2003) with severe neurological manifestations (Quartier et al., 2000) . Moreover, 313 patients with a-or hypogammaglobulinemia can also develop chronic HPeV1 314 infection (van de Ven et al., 2011) , as well as HPeV3 myocarditis and encephalitis 315 that are extremely uncommon in adults (Mardekian et al., 2015) . Individuals 316 undergoing immunosuppressive therapy further support the critical role of antibody 317 responses in the control of picornaviruses. For instance, cancer treatment with 318 rituximab leads to prolonged B-cell deficiency and hypogammaglobulinemia and 319 patients receiving such therapy are susceptible to severe and even lethal enterovirus 320 infections (Servais et al., 2010) . 321
Direct confirmation for the role of antibodies in picornavirus infections comes 322 from controlled infections in animal models. Experimental infections in mice with 323 different immunodeficiencies proved the significance of adaptive responses: whereas 324 up to 70% of mice deficient in innate immune responses survived EV71 infection, 325 mice with severe combined immunodeficiency developed limb paralysis and died in 326 almost 100% of cases (Liao et al., 2014) . In Theiler's encephalomyelitis virus 327 (TMEV)-infected mice-a common model for neurotropic picornaviruses-328 immunosuppression with anti-IgM antibodies led to virus-induced demyelinization 329 (Rodriguez et al., 1990) . 330
At the moment there are no antivirals for treatment of severe picornavirus 331 infections (Linden et al., 2015; Wildenbeest et al., 2010) and the only therapeutic 332 option is intravenous immunoglobulin (IVIG). However, because of the low BBB 333 permeability to antibodies, IVIG is rarely effective in CNS infections although 334 intraventricular immmunoglobulin administration may be beneficial (Quartier et al., 335 2000) . Antibodies can also be effective at mucosal sites and prevent picornavirus 336 viremia and CNS invasion (Nathanson & Bodian, 1962) . Successful management of 337 severe picornavirus infections using IVIG (Wildenbeest et al., 2013) indicates the 338 potential efficacy of passive immunization to control picornavirus infections. 339
However, the presence of specific neutralizing antibodies and their titres cannot be 340 controlled in IVIG preparation, and the reliable options of passive immunization 341 against picornaviruses should be based on the production of specific neutralizing or 342 broadly neutralizing antibodies that target known viral epitopes. Production of 343 specific antibodies could also contribute to rapid and specific serology-based 344 diagnostics of picornavirus infections that are beneficial at time-critical point-of-care 345 setups. In addition to passive immunization, the success of the polio vaccine 346 encourages development of vaccines against other picornaviruses. Controlling 347 picornavirus infections with vaccines is not a feasible approach for the entire 348
Picornaviridae family, but can be realistic for some virus types. Both vaccine and 349 antibody development require thorough understanding of viral neutralization, and 350 below we summarize the current knowledge of the neutralization of CNS-invading 351 picornaviruses. 352
NEUTRALIZATION OF PICORNAVIRUSES 353
Neutralization of EV71 and CVA16 354
EV71 is genetically diverse and contains 14 genotypes: A, B1-B5, C1-C5, D, E, and 355 F (Bessaud et al., 2014) ; C4 is further classified into two lineages C4a and C4b 356 (Zhang et al., 2010a) . Genotypes B3, B4, B5, C1, C2, C4 and C5 contributed to recent 357 outbreaks (Chong et al., 2015) . CVA16 is less genetically diverse showing relatively 358 slower evolutionary rate and has 3 genotypes: A, B1 (B1a, B1b, B1c) and B2 (Zhang 359 et al., 2010b) . EV71 can undergo intra-and intergenotype shifts that occur due to 360 recombination events during co-circulation with CVA16 or different EV71 genotypes 361 and correlate with most outbreaks (Bible et al., 2007) . An effective vaccine should 362 neutralize multiple serotypes of EV71 and also CVA16. This necessity underpins 363 difficulties in EV71 vaccine development. 364
The first live-attenuated vaccine strain was reported by Arita et al. in 2005. It 365 induced broadly-neutralizing responses in immunized monkeys, but was neurotropic 366 when inoculated intravenously and its further development was halted (Arita et al., 367 2007) . Development of inactivated vaccines was more successful: five such vaccines 368 developed by different organizations entered clinical trials and three of them have 369 already completed Phase III showing 80.4-97.4% efficacy against EV71-induced 370 HFMD in humans (Liu et al., 2015a) . Two C4-based vaccines developed by the 371 Chinese Academy for Medical Sciences (CAMS) and Sinovac Biotech Co Ltd were 372 approved by the Chinese Food and Drug Administration (CFDA) as of January 2016 373 (Mao et al., 2016) . In addition to live-attenuated and inactivated vaccines, virus-like 374 particle (VLP) vaccine candidates were generated in baculovirus or Saccharomyces 375 cerevisiae systems using co-expression of viral protein precursor P1 with viral 376 protease 3CD (Chung et al., 2008; Li et al., 2013) . The VLP vaccine candidate 377 produced in baculovirus system showed promise in in vivo studies: the survival rate of 378 VLP-immunized mouse pups after lethal EV71 challenge was superior to those 379 immunized with inactivated virus (Chung et al., 2008) and it also induced protective 380 responses in monkeys . The approved inactivated vaccines cross-381 protected against B1, B5 and C4a (CAMS vaccine) (Chou et al., 2013) and B4, B5, 382 C2 and C5 (Sinovac vaccine) (Mao et al., 2013) ; VLP vaccines protected monkeys 383 against B4, B5, C3, C4 and C5 , but none of them neutralized 384
CVA16. 385
Multivalent vaccines may offer protection against EV71 and co-circulating 386
CVA. Bivalent EV71/CVA16 vaccines based on inactivated viruses or VLP can elicit 387
high titres of neutralizing antibodies in immunized mice and protect from EV71 and 388 CVA16 infections (Ku et al., 2014) . Yet broader protection is desired to mitigate 389 other HFMD contributors, such as coxsackievirus A6 (CVA6) , and 390 one trivalent EV71/CVA16/CVA6 inactivated vaccine candidate protecting mice 391 from lethal challenge with these viruses was reported (Caine et al., 2015) . 392
Peptide vaccines consisting of well-defined neutralizing epitopes represent a 393 promising approach to target against several heterologous viruses (Li et al., 2014a) . 394
They are easier to produce compared to inactivated virus vaccines, do not require 395 handling live virus and allow immunization with lower protein load. Neutralizing 396 epitopes on EV71 are localized on viral structural proteins VP1, VP2 and VP3 (Fig. 3  397 (a) and (b)). Three continuous neutralizing epitopes have been localized to VP1 398 residues 163-177 (known as SP55) and 215-219 (part of SP70 which localizes to 399 residues 208-222) and to region 240-260 (Chang et al., 2010; Foo et al., 2007; Lim et 400 al., 2012) . SP55 has 85-100% sequence identity within A-C4 groups (Foo et al., 401 2007) and SP70 is 100% conserved across EV71 genotypes A-C4 and thus is 402 universal for them. In addition, VP1 encompasses a strain-specific discontinuous 403 neutralization epitope at the 5-fold symmetry axis with residue 145 critically 404 contributing to antibody interaction (Lee et al., 2013) . Two other neutralizing 405 epitopes were localized to residues 136-150 of VP2 (known as VP2-28) (Liu et al., 406 2011) , and to VP3 residues 55-69 that form a "knob" and are 100% conserved across 407 EV71 subgenogroups A-C4 (Kiener et al., 2014) . Much less is known about 408 neutralizing epitopes in CVA16. Most of the experimentally proven neutralizing 409 epitopes of CVA16 were localized to VP1 (GH, EF, C-terminal loops and B and C β-410 sheets) (Ren et al., 2015; Shi et al., 2013) ; one more continuous epitope was found in 411 GH loop of VP3 (Chong et al., 2012) (Fig 3 (b) ). Additional antigenic sites of CVA16 412 were predicted in silico in EF and HI loops of VP2 (Ren et al., 2015) . Although 413 peptide vaccines are usually less immunogenic compared to the viral particles, this 414 can be mitigated using adjuvants or fusing viral epitopes with highly immunogenic 415 antigens. Using such an approach, a tandem of three well described EV71 epitopes-416 SP55, SP70 and VP2-28-separated by Gly-Ser linker and fused to thioredoxin was 417 expressed in E. coli. The recombinant protein induced EV71-specific neutralizing 418 responses in immunized mice, serving as a proof-of-concept for peptide vaccines 419 against HFMD (Li et al., 2014b) . In another study, a hepatitis B virus-like particle 420 displaying EV71 SP55 and VP2-28 epitopes induced neutralizing responses in 421 immunized mice, and could also be cross-protective against CVA16 (Xu et al., 422 2015b) . In terms of immunogenicity EV71 is one of the best-studied picornaviruses 423 with two EV71 vaccines approved by CFDA and further work will be driven by the 424 necessity of multivalent HFMD vaccines. 425 426
Neutralization of enterovirus 68 427
EV68 is an emerging virus and little is known about its antigenicity. Imamura et al. 428 studied the immunogenic properties of twelve EV68 genotypes belonging to all three 429 genetic lineages of EV68-A, B and C (Imamura et al., 2013) . Immunized guinea 430 pigs generated high titres of neutralizing antibodies to the original virus and to viruses 431 of the same lineage, but very little cross-neutralization between genetic lineages was 432 found (Imamura et al., 2014) . Importantly, the majority of sequence variation between 433 EV68 lineages is localized to the VP1 BC and DE surface loops (Imamura et al., 434 2013 (Imamura et al., 434 , 2014 Liu et al., 2015b) , which are the most variable and likely are epitope-435 containing in enteroviruses. Indeed, VP1 likely contains antigenic determinants as the 436 increase in its gene diversity correlates with an increase in the number of EV68 437 detections (Meijer et al., 2012) , reflecting the appearance of antigenically new viruses 438 in the population. Substitution dynamics within the viral genome also suggests the 439 localization of antigenic epitopes to VP1: several positions in VP1 BC and DE loops 440 ( Fig. 3 (b) ) are undergoing positive selection and might be associated with antigenic 441 differences between EV68 genetic lineages (Imamura et al., 2014) . Nevertheless, to 442 date the exact immunogenic epitopes of EV68 are only predictive and have not been 443
mapped. 444
Not much is also known about the distribution of EV68 neutralizing antibodies 445 in human population. One study done in Finland addressed this question reporting 446 high titres of neutralizing responses to EV68 in 80% of the studied individuals (Smura 447 et al., 2010) . However, neutralization responses in this study were addressed against 448 the prototype EV68 Fermon strain, which is antigenically very different from the 449 currently circulating EV68 strains (Greninger et al., 2015; Meijer et al., 2012) . 450 Therefore, neither EV68 antigenicity, nor the population protection levels are 451 understood well at the moment. 452 453
Neutralization of HPeV3 454 455
Almost nothing is known about HPeV3 antigenicity. Of the parechoviruses, only 456 antigenicity of HPeV1 has been studied (Shakeel et al., 2015) and so far three 457 neutralizing epitopes on HPeV1 structural proteins VP0, VP1 and VP3 are described. 458
One is localized to residues 83-97 of VP0 (Joki-Korpela et al., 2000) , another is found 459 on VP1 and encompasses receptor recognizing arginine-glycine-aspartic acid (RGD) 460 motif (Alho et al., 2003) and the third one is formed by VP0 and VP3 (Shakeel et al., 461 2015; Westerhuis et al., 2015) . Whereas antisera generated against HPeV1 VP0 462 peptide was not tested for HPeV3 neutralization, two other monoclonal antibodies did 463 not cross-react with HPeV3 (Shakeel et al., 2015; Westerhuis et al., 2015) . For 464
HPeV3 only non-neutralizing epitope has been described (Shakeel et al., 2016) 465 The data on HPeV3 seroprevalence in population is also sparse. A study of 466 sera from populations in Finland and Netherlands revealed neutralizing responses to 467
HPeV3 only in about 10% of the samples and very low titres of neutralizing 468 antibodies post infection (Westerhuis et al., 2013) . On the contrary, researchers in 469 Japan detected neutralizing responses to HPeV3 in 67% of individuals between 7 470 months and 40 years old (Ito et al., 2004) , and reported high titres of neutralizing 471 antibodies after 3 months post infection in all studied individuals (Aizawa et al., 472 2015) . The virus strains used in European and Japanese studies were different, 473
suggesting that some strains of HPeV3 are strongly immunogenic, whereas others are 474 not. The determinants of immunogenicity within this virus are currently unknown and 475 investigation of the Japanese A308/99 strain immunogenicity may shed light on the 476 neutralization of HPeV3. 477
The treatment option for human parechovirus infections could be IVIG 478 (Wildenbeest et al., 2013) , but titres of neutralizing antibodies against HPeV3 in 479
European IVIG preparations are very low (Westerhuis et al., 2012) . Developing 480 vaccines does not seem feasible because subjects of severe HPeV3 infections are 481 infants. Passive immunization protects against HPeV3 (Aizawa et al., 2015) thus 482 developing therapeutic antibodies is a necessity for which studies of HPeV3 483 antigenicity are required. 484
485
CONCLUSIONS AND FUTURE PERSPECTIVES 486
Our understanding of antigenicity of picornaviruses that target CNS is very poor and 487 is largely limited to studies of EV71. Although studies of EV71 have already resulted 488 in two CFDA-approved HFMD vaccines, multivalent HFMD vaccines to control 489 different EV71 genotypes and also co-circulating CVA16 are the next goal. Proof-of-490 concept studies of such vaccines are promising (Caine et al., 2015; Sun et al., 2014) , 491 but further work is needed to identify the optimal combination of antigens for 492 balanced, broadly protective immunity. Targeting multiple viruses with a single shot 493 also requires delivery systems for effective presentation of multiple epitopes. In this 494 regard, VLP and peptide vaccines may be preferable over inactivated vaccines, 495 offering tailored solutions in terms of presented antigens together with comparable 496 immunogenicity, high safety and less tedious production, and economical feasibility 497 (Li et al., 2014a) . 498
We know almost nothing about EV68 and HPeV3 antigenicity. Classical 499 approach to study virus antigenicity and develop vaccines relies on animal models, 500 which is just being developed for EV68 and not available for HPeV3, hampering 501 investigation of these viruses. Therefore, their antigenicity should be studied directly 502 from human sera using novel methods, such as peptide arrays (Hansen et al., 2013) , 503 classical phage display or phage display enhanced with next generation sequencing 504 (NGS) (Christiansen et al., 2015) . Successful use of custom phage display library and 505 NGS was reported by Xu et al. who analysed antibody-peptide interactions in sera of 506 over 550 donors and identified numerous previously undescribed viral epitopes, 507
proving the utility of NGS-enhanced phage display for epitope identification (Xu et 508 al., 2015a) . 509
Another future direction is the search for EV68 and HPeV3 neutralizing 510 antibodies. In the absence of antivirals (Linden et al., 2015; Wildenbeest et al., 2010) , 511 such antibodies could be valuable therapeutics, especially for HPeV3 that infects 512 infants for whom vaccination is not a suitable option. A useful approach for that is 513 identification of individual's immune response to a given virus followed by respective 514 B-cell cloning (Kwakkenbos et al., 2014) . This approach was utilized to generate two 515 broadly neutralizing antibodies against HPeV (Shakeel et al., 2015; Westerhuis et al., 516 2015) . Unfortunately, these antibodies did not neutralize HPeV3. High throughput 517 approaches, such as sequencing of antibody repertoire (Georgiou et al., 2014) and 518 screening of large antibody fragments libraries using ribosomal, bacterial, yeast or 519 phage display (Bradbury et al., 2011) are also utilized for antibody discovery. For 520 instance, phage display technology has already yielded monoclonal neutralizing 521 antibodies with therapeutic potential for EV71 (Zhang et al., 2015) . Over 50 phage-522 display derived antibodies have been approved by the U.S. Food and Drug 523 Administration (FDA) or European Medicines Agency (EMA) as of May, 2016. 524 About 500 antibodies are undergoing clinical trials. These include antibodies targeting 525 infectious agents, for example Rabies virus, which is now in Phase II (Frenzel et al., 526 2016) . 527
Overall, picornaviruses antigenicity and neutralization studies have already 528 brought encouraging results, however more challenges are ahead. The detailed 529
understanding of viral immunogenicity is clearly an important task to focus on, but it 530 should be carried out in parallel with broader studies of viral biology and spread. 531
Although many research groups in Europe, US and Asia are very active in the field of 532 picornavirus research, we are still far from a thorough understanding of viral 533 epidemiology, pathogenesis, evolution and inhibition, which are necessary for 534 effective virus control. Apart from scientific challenges, development protective 535 measures against picornaviruses may face additional financial and regulatory 536 difficulties due to the endemic nature of diseases that they cause. Hence, drawing the 537 public attention to the health care threats that picornaviruses impose is another 538 important activity area for the medical and scientific communities. 
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